A Patient Charter for Chronic Urticaria.
Angioedema
Chronic urticaria
Health care
Hives
Patient advocacy
Wheals
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
29
09
2023
accepted:
30
10
2023
medline:
22
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
aheadofprint
Résumé
Chronic urticaria (CU) is the recurring development of wheals (aka "hives" or "welts"), angioedema, or both for more than 6 weeks. Wheals and angioedema occur with no definite triggers in chronic spontaneous urticaria, and in response to known and definite physical triggers in chronic inducible urticaria. Approximately 1.4% of individuals globally will have CU during their lifetime. The itching and physical discomfort associated with CU have a profound impact on daily activities, sexual function, work or school performance, and sleep, causing significant impairment in a patient's physical and mental quality of life. CU also places a financial burden on patients and healthcare systems. Patients should feel empowered to self-advocate to receive the best care. The voice of the patient in navigating the journey of CU diagnosis and management may improve patient-provider communication, thereby improving diagnosis and outcomes. A collaboration of patients, providers, advocacy organizations, and pharmaceutical representatives have created a patient charter to define the realistic and achievable principles of care that patients with CU should expect to receive. Principle (1): I deserve an accurate and timely diagnosis of my CU; Principle (2): I deserve access to specialty care for my CU; Principle (3): I deserve access to innovative treatments that reduce the burden of CU on my daily life; Principle (4): I deserve to be free of unnecessary treatment-related side-effects during the management of my CU; and Principle (5): I expect a holistic treatment approach to address all the components of my life impacted by CU. The stated principles may serve as a guide for healthcare providers who care for patients with CU and translate into better patient-physician communication. In addition, we urge policymakers and authors of CU treatment guidelines to consider these principles in their decision-making to ensure the goals of the patient are achievable.
Identifiants
pubmed: 37991694
doi: 10.1007/s12325-023-02724-6
pii: 10.1007/s12325-023-02724-6
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–66.
pubmed: 34536239
doi: 10.1111/all.15090
Kolkhir P, Pogorelov D, Darlenski R, Caminati M, Tanno LK, Le Pham D, et al. Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organ J. 2018;11:14.
pubmed: 29988758
pmcid: 6030778
doi: 10.1186/s40413-018-0193-4
Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–7.
pubmed: 24766875
doi: 10.1016/j.jaci.2014.02.036
Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75:423–32.
pubmed: 31494963
doi: 10.1111/all.14037
Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14:100533.
pubmed: 34221215
pmcid: 8233382
doi: 10.1016/j.waojou.2021.100533
Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184:226–36.
pubmed: 32956489
doi: 10.1111/bjd.19561
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticarial. A GA2LEN task force report. Allergy. 2011;66:317–30.
pubmed: 21083565
doi: 10.1111/j.1398-9995.2010.02496.x
Sánchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organ J. 2021;14:100546.
pubmed: 34141049
pmcid: 8188551
doi: 10.1016/j.waojou.2021.100546
Silpa-archa N, Kulthanan K, Pinkaew S. Physical urticaria: prevalence, type and natural course in a tropical country. J Eur Acad Dermatol Venereol. 2011;25:1194–9.
pubmed: 21175877
doi: 10.1111/j.1468-3083.2010.03951.x
Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72:2005–16.
pubmed: 28543019
doi: 10.1111/all.13209
Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient. 2015;8:551–8.
pubmed: 26476961
pmcid: 4662955
doi: 10.1007/s40271-015-0145-9
Hoskin B, Ortiz B, Paknis B, Kavati A. Humanistic burden of refractory and nonrefractory chronic idiopathic urticaria: a real-world study in the United States. Clin Ther. 2019;41:205–20.
pubmed: 30606639
doi: 10.1016/j.clinthera.2018.12.004
Huang Y, Xiao Y, Zhang X, Li J, Chen X, Shen M. A meta-analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety. Front Med (Lausanne). 2020;7:39.
pubmed: 32175322
doi: 10.3389/fmed.2020.00039
Goldstein S, Eftekhari S, Mitchell L, Winders TA, Kaufman L, Dudas D, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99:1091–8.
pubmed: 31396637
Tomaszewska K, Słodka A, Tarkowski B, Zalewska-Janowska A. Neuro-immuno-psychological aspects of chronic urticaria. J Clin Med. 2023;12:3134.
pubmed: 37176575
pmcid: 10179371
doi: 10.3390/jcm12093134
Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, et al. Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: a real-world study in the United States. Allergy Asthma Proc. 2018;39:201–11.
pubmed: 29514728
doi: 10.2500/aap.2018.39.4129
Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: Newer generation H(1)-antihistamines are safer than first-generation H(1)-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.
pubmed: 31582993
pmcid: 6771107
doi: 10.1186/s13223-019-0375-9
Caffarelli C, Paravati F, El Hachem M, Duse M, Bergamini M, Simeone G, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45:101.
pubmed: 31416456
pmcid: 6694633
doi: 10.1186/s13052-019-0695-x
Chung WH, Chu CY, Huang YH, Wang WM, Yang CH, Tsai TF. Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria. J Formos Med Assoc. 2016;115:968–80.
pubmed: 26679383
doi: 10.1016/j.jfma.2015.09.009
Hacard F, Giraudeau B, d’Acremont G, Jegou MH, Jonville-Bera AP, Munck S, et al. Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol. 2021;185:658–60.
pubmed: 33913519
pmcid: 8457139
doi: 10.1111/bjd.20415
Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45:547–65.
pubmed: 25711134
doi: 10.1111/cea.12494
Esteves Caldeira L, Paulino M, Coutinho C, Neto M, Pereira Barbosa M, Costa C. Clinical experience of a specialized urticaria outpatient clinic from a Portuguese UCARE. Eur Ann Allergy Clin Immunol. 2023;55:9–18.
pubmed: 33949172
doi: 10.23822/EurAnnACI.1764-1489.209
Maurer M, Weller K, Magerl M, Maurer RR, Vanegas E, Felix M, et al. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: a UCARE study. World Allergy Organ J. 2020;13: 100475.
pubmed: 33204387
pmcid: 7606865
doi: 10.1016/j.waojou.2020.100475
CRUSE - chronic urticaria self evaluation app [Internet]. UCARE Network; 2022 [cited 2023 July 5]. Available from: https://ga2len-ucare.com/cruse-chronic-urticaria-self-evaluation-app/ .
Bansal CJ, Bansal AS. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2019;15:56.
pubmed: 31528163
pmcid: 6737621
doi: 10.1186/s13223-019-0372-z
Zuberbier T, Pfrommer C, Specht K, Vieths S, Bastl-Borrmann R, Worm M, et al. Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria. J Allergy Clin Immunol. 2002;109:343–8.
pubmed: 11842307
doi: 10.1067/mai.2002.121309
Mathelier-Fusade P. Drug-induced urticarias. Clin Rev Allergy Immunol. 2006;30:19–23.
pubmed: 16461991
doi: 10.1385/CRIAI:30:1:019
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71:780–802.
pubmed: 26991006
doi: 10.1111/all.12884
Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, Dykewicz M, et al. Optimizing value in the evaluation of chronic spontaneous urticaria: a cost-effectiveness analysis. J Allergy Clin Immunol Pract. 2020;8:2360-9.e1.
pubmed: 31751758
doi: 10.1016/j.jaip.2019.11.004
Oliver ET, Hogan MB. Eliminating low-value medical care in chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2020;8:2370–1.
pubmed: 32620436
doi: 10.1016/j.jaip.2020.04.065
Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy. 2013;68:816–9.
pubmed: 23646863
doi: 10.1111/all.12153
Ryan D, Tanno LK, Angier E, Clark E, Price D, Zuberbier T, et al. Clinical review: the suggested management pathway for urticaria in primary care. Clin Transl Allergy. 2022;12: e12195.
pubmed: 36225262
pmcid: 9533216
doi: 10.1002/clt2.12195
Ryan D, Angier E, Gomez M, Church D, Batsiou M, Nekam K, et al. Results of an allergy educational needs questionnaire for primary care. Allergy. 2017;72:1123–8.
pubmed: 28122131
doi: 10.1111/all.13134
Cho YT, Pao YC, Chu CY. Unmet medical needs for chronic spontaneous urticaria patients: highlighting the real-life clinical practice in Taiwan. J Eur Acad Dermatol Venereol. 2016;30:41–9.
pubmed: 26428436
doi: 10.1111/jdv.13357
Cherrez A, Maurer M, Weller K, Calderon JC, Simancas-Racines D, Cherrez OI. Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. World Allergy Organ J. 2017;10:21.
pubmed: 28546850
pmcid: 5440895
doi: 10.1186/s40413-017-0150-7
Weller K, Viehmann K, Bräutigam M, Krause K, Siebenhaar F, Zuberbier T, et al. Management of chronic spontaneous urticaria in real life–in accordance with the guidelines? A cross-sectional physician-based survey study. J Eur Acad Dermatol Venereol. 2013;27:43–50.
pubmed: 22150693
doi: 10.1111/j.1468-3083.2011.04370.x
Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, et al. Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. Allergy. 2016;71:1210–8.
pubmed: 27038243
doi: 10.1111/all.12901
Maurer M, Staubach P, Raap U, Richter-Huhn G, Baier-Ebert M, Chapman-Rothe N. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol. 2016;174:892–4.
pubmed: 26406483
doi: 10.1111/bjd.14203
Anto A, Maurer R, Gimenez-Arnau A, Cherrez-Ojeda I, Hawro T, Magerl M, et al. Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. Allergy. 2021;76:3810–3.
pubmed: 34437706
doi: 10.1111/all.15061
Cherrez-Ojeda I, Vanegas E, Cherrez A, Felix M, Weller K, Magerl M, et al. Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clin Transl Allergy. 2021;11: e12089.
pubmed: 34962721
pmcid: 8684305
doi: 10.1002/clt2.12089
Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.
pubmed: 23432142
doi: 10.1056/NEJMoa1215372
Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “Real-world” evidence. JAMA Dermatol. 2019;155:29–38.
pubmed: 30427977
doi: 10.1001/jamadermatol.2018.3447
Yosipovitch G, Biazus Soares G, Mahmoud O. Current and emerging therapies for chronic spontaneous urticaria: a narrative review. Dermatol Ther (Heidelb). 2023. https://doi.org/10.1007/s13555-023-00972-6 .
doi: 10.1007/s13555-023-00972-6
pubmed: 37386330
pmcid: 10366054
Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: collegium internationale allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;181:321–33.
pubmed: 32224621
doi: 10.1159/000507218
Hopkinson K. The role of patient-reported outcomes in the management of chronic spontaneous urticaria. Br J Nurs. 2019;28:144–50.
pubmed: 30746981
doi: 10.12968/bjon.2019.28.3.144
Baiardini I, Fasola S, Maurer M, Weller K, Canonica GW, Braido F. Minimal important difference of the chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy. 2019;74:2542–4.
pubmed: 31169906
doi: 10.1111/all.13939
Kulthanan K, Chularojanamontri L, Tuchinda P, Rujitharanawong C, Baiardini I, Braido F. Minimal clinical important difference (MCID) of the Thai chronic urticaria quality of life questionnaire (CU-Q2oL). Asian Pac J Allergy Immunol. 2016;34:137–45.
pubmed: 27007835
Prosty C, Gabrielli S, Mule P, Noorah N, Baum S, Greenberger S, et al. Validation of the urticaria control test (UCT) in children with chronic urticaria. J Allergy Clin Immunol Pract. 2022;10(3293–8): e2.
Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy. 2011;66:840–4.
pubmed: 21385184
doi: 10.1111/j.1398-9995.2011.02580.x
Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M. Clinical measures of chronic urticaria. Immunol Allergy Clin North Am. 2017;37:35–49.
pubmed: 27886909
doi: 10.1016/j.iac.2016.08.005
Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, et al. Development and validation of the cholinergic urticaria quality-of-life questionnaire (CholU-QoL). Clin Exp Allergy. 2018;48:433–44.
pubmed: 29369455
doi: 10.1111/cea.13102
Ahsan DM, Altrichter S, Gutsche A, Bernstein JA, Altunergil T, Brockstaedt M, et al. Development of the cold urticaria activity score. Allergy. 2022;77:2509–19.
pubmed: 35403217
doi: 10.1111/all.15310
MOXIE_Non-commercial use [Internet]. 2023 [cited 2023 Sep 18]. Available from: https://moxie-gmbh.de/our-products/non-commercial-use/?p=1 .
Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76:2965–81.
pubmed: 33539587
doi: 10.1111/all.14757
Weller K, Ohanyan T, Hawro T, Ellrich A, Sussman G, Koplowitz J, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73:2406–8.
pubmed: 30076605
doi: 10.1111/all.13586
Deza G, Bertolin-Colilla M, Pujol RM, Curto-Barredo L, Soto D, Garcia M, et al. Basophil fcepsilonri expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017;97:698–704.
pubmed: 28303277
doi: 10.2340/00015555-2654
Curto-Barredo L, Archilla LR, Vives GR, Pujol RM, Giménez-Arnau AM. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98:641–7.
pubmed: 29648675
doi: 10.2340/00015555-2941
Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459–66.
pubmed: 20146728
doi: 10.1111/j.1398-9995.2009.02325.x
Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(1139–50): e4.
Gilmore TM, Alexander BH, Mueller BA, Rivara FP. Occupational injuries and medication use. Am J Ind Med. 1996;30:234–9.
pubmed: 8844055
doi: 10.1002/(SICI)1097-0274(199608)30:2<234::AID-AJIM16>3.0.CO;2-Y
Zhou P, Zeng S, Fu L, Chen H, Li L. Efficacy and safety of intensive nonsedating antihistamines for chronic spontaneous urticaria: a meta-analysis of randomized controlled trials. Int Arch Allergy Immunol. 2022;183:796–803.
pubmed: 35144258
doi: 10.1159/000521900
Weller K, Ziege C, Staubach P, Brockow K, Siebenhaar F, Krause K, et al. H 1 -antihistamine up-dosing in chronic spontaneous urticaria: patients’ perspective of effectiveness and side effects – a retrospective survey study. PLoS ONE. 2011;6: e23931.
pubmed: 21909407
pmcid: 3164658
doi: 10.1371/journal.pone.0023931
Tayefi M, Bradley M, Neijber A, Fastberg A, Ceynowa D, Eriksson M. Chronic urticaria: a Swedish registry-based cohort study on population, comorbidities and treatment characteristics. Acta Derm Venereol. 2022;102:adv00624.
pubmed: 34877606
doi: 10.2340/actadv.v101.737
Lachover-Roth I, Rabie A, Cohen-Engler A, Rosman Y, Meir-Shafrir K, Confino-Cohen R. Chronic urticaria in children - new insights from a large cohort. Pediatr Allergy Immunol. 2021;32:999–1005.
pubmed: 33502063
doi: 10.1111/pai.13457
Torre AC, Bollea Garlatti ML, Marciano S, Posadas-Martinez ML, Parisi CAS, Mazzuoccolo LD. Real-life approach and treatment of chronic urticaria in Argentina: a national survey. Dermatol Ther. 2019;32: e13086.
pubmed: 31513726
doi: 10.1111/dth.13086
Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.
pubmed: 30214247
pmcid: 6121746
doi: 10.2147/JAA.S176026
Global Initiative for Asthma (GINA) 2022 Report: global strategy for asthma management and prevention. [Internet]. 2022 [cited 2022 Aug 3]. Available from: https://ginasthma.org/gina-reports/ .
Menzies-Gow A, Jackson DJ, Al-Ahmad M, Bleecker ER, Cosio Piqueras FBG, Brunton S, et al. A renewed charter: key principles to improve patient care in severe asthma. Adv Ther. 2022;39:5307–26.
pubmed: 36251167
pmcid: 9573814
doi: 10.1007/s12325-022-02340-w
Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Maurer M, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2018;73:576–84.
pubmed: 29058822
doi: 10.1111/all.13339
Özkan M, Oflaz SB, Kocaman N, Özşeker F, Gelincik A, Büyüköztürk S, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2007;99:29–33.
pubmed: 17650826
doi: 10.1016/S1081-1206(10)60617-5
Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006;54:420–6.
pubmed: 16488292
doi: 10.1016/j.jaad.2005.11.1103
Ogłodek EA, Szota AM, Just MJ, Araszkiewicz A, Szromek AR. Sense of alexithymia in patients with anxiety disorders comorbid with recurrent urticaria. Neuropsychiatr Dis Treat. 2016;12:995–1004.
pubmed: 27143899
pmcid: 4844460
doi: 10.2147/NDT.S94600
Sommer R, da Silva N, Langenbruch A, Maurer M, Staubach-Renz P, Augustin M. Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. Eur J Dermatol. 2020;30:259–66.
pubmed: 32666926
doi: 10.1684/ejd.2020.3763
Deciding how to manage chronic spontaneous urticaria (CSU) [Internet]. Global Allergy & Airways Patient Platform; 2021 [cited 2023 Sep 1]. Available from: https://gaapp.sdm.health/ .
Cherrez-Ojeda I, Vanegas E, Cherrez A, Felix M, Weller K, Magerl M, et al. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. World Allergy Organ J. 2021;14: 100542.
pubmed: 34141048
pmcid: 8190491
doi: 10.1016/j.waojou.2021.100542
Urticaria day [Internet]. 2023 [cited 2023 July 6]. Available from: https://urticariaday.org/ .
Lovering C. Where to find a support group for chronic idiopathic urticaria. [Internet]. 2021 [cited 2023 Sept 1]. Available from: https://www.healthline.com/health/ciu/chronic-idiopathic-urticaria-support-groups#types-of-support-groups .
Drexel C, Bixler E, Lee J, Lang D, Eftekhari S. Online education with the patient voice highlights continuous gaps in care and needs for therapeutic options for chronic spontaneous urticaria (CSU) management. J Allergy Clin Immunol. 2023;151:AB138.
doi: 10.1016/j.jaci.2022.12.430
Laires PA, Balp MM, Weller K, Winders T, Bernstein JA, O'Donoghue JEM, et al. Urticaria voices: design of a real-world study on the burden of chronic urticaria from patients' and physicians' perspectives. European Academy of Dermatology and Venereology; 2022. September 7-10; Milan, Italy